TIVA includes the use of multiple intravenous agents. In the following review, the pharmacology of key intravenous agents and their current uses are summarised. This review will then characterise challenges and offer an opinion on the benefits and disadvantages of TIVA in clinical practice, both in general practice and during a COVID pandemic. A comparison of common criticisms regarding TIVA in current clinical practice and recent research milestones that will further enable the use of TIVA and warrant future research. Further adaptation for ease of use, mitigation of its complications, and advances in pharmacokinetic delivery will allow for better and contextual use of TIVA.